Arcutis Biotherapeutics Inc
NASDAQGS:ARQT
United States / Healthcare / Biotechnology
ARQT News
Welcome to Your News Upgrade
Be the First to Know and Act on Market Moving News.
Arcutis and Padagis Agree to Stay Patent Lawsuit
WESTLAKE VILLAGE, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing...
Arcutis and Padagis agree to stay patent litigation
WESTLAKE VILLAGE, Calif. - Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a biopharmaceutical company focused on immuno-dermatology treatments with a market capitalization of $1.81...
Arcutis Biotherapeutics and Padagis Agree to Stay Patent Lawsuit
Arcutis Biotherapeutics (NASDAQ:ARQT), Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, is...
Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference
WESTLAKE VILLAGE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing...
Arcutis Biotherapeutics CEO sells $64,413 in stock
Todd Franklin Watanabe, President and CEO of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a $1.96 billion market cap company that has seen an impressive 87% surge in share price...
Artiva Biotherapeutics stock rises following analyst optimism
Investing.com -- Shares of Artiva Biotherapeutics Inc (NASDAQ:ARTV) climbed 2.5% as the company received positive comments from H.C. Wainwright analyst Edward White. The uptick...
ARQT Stock Hits 52-Week High at $17.73 Amid Strong Growth
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) stock soared to a 52-week high of $17.73, marking a significant milestone for the $2.07 billion market cap biopharmaceutical company....
Arcutis biotherapeutics CEO Todd Franklin Watanabe sells shares worth $21,137
In recent transactions, Todd Franklin Watanabe, President and Chief Executive Officer of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a $1.99 billion market cap company whose stock...
ARQT Stock Hits 52-Week High at $16.32 Amidst Strong Yearly Growth
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) stock soared to a 52-week high, reaching a price level of $16.32. With a market capitalization of $1.78 billion and impressive gross...
Jefferies lifts Arcutis stock price target to $19, retains Buy rating
On Tuesday, Jefferies, a well-known financial services company, increased its price target for Arcutis Biotherapeutics Inc . (NASDAQ: NASDAQ:ARQT) shares to $19.00, up from the...